| Description | BR102910 (4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]-) is a selective inhibitor of fibroblast activated protein (FAP). |
| In vivo | 4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]-(C57BL/6J mice, 0-30 mg/kg, orally, once) showed significant FAP inhibition in a dose dependent manner [1]. |
| Synonyms | 4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]- |
| molecular weight | 459.3 |
| Molecular formula | C18H14Cl2F2N4O2S |
| CAS | 2505339-54-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 55 mg/mL (119.75 mM) |
| References | 1. Hui Jin Jung, et al. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor. Bioorg Med Chem Lett. 2021 Apr 1;37:127846. |